The Week in Review: ChinaBio® Investor Forum Held in Tianjin

The 7th ChinaBio® Investor Forum granted “Most Promising Company” awards to Sinocro Medical of Tianjin, a medical device company, and vaccine company Tianjin CanSino Biotechnolo; Concord Medical Services Holdings plans a $126 million IPO on the NYSE; FORMA Therapeutics, which has a lab at Tsinghua University, closed a $25.5 million Series B round; PPD, Inc. announced it spent $77 million to buy fellow CRO BioDuro; China’s MoHRSS released the 2009 version of the National Drug Reimbursement List; Bayer Schering Pharma received SFDA approval for an MS drug; Tianyin Pharma forecast a 75% improvement in fiscal year 2011 results and received SFDA approval for two TCM products; Simcere Pharma (先声药业) has quality control problems at its new vaccine subsidiary; Sinovac received another 1 million dose order for its H1N1 vaccine; China Sky One Medical (中国天字一号医药公司) signed up a sales agent in Southeast Asia for two diagnostic kits; AlphaRx will establish an R&D facility in Shanghai's Zhangjiang park; AstraZeneca will move much of its API production to China. More details... Stock symbols: (NYSE: CCM) (NSDQ: PPDI) (XE: SCH) (NYSE Alternext: TPI) (NYSE: SCR) (NYSE: SVA) (NSDQ: CSKI) (OTCBB: ALRX) (NYSE: AZN)